Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 12, 2012, Pages 1379-1385

  Gisbert, J P ^a   Menchen L ^b   Garcia Sanchez V ^c   Marin I ^b   Villagrasa, J R ^a   Chaparro, M ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; HEPATITIS B ANTIBODY; MESALAZINE; RECOMBINANT HEPATITIS B VACCINE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL PROTOCOL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CROHN DISEASE; DRUG DOSE COMPARISON; DRUG EFFICACY; ENTERITIS; FEMALE; HEPATITIS B; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTIPLE DRUG DOSE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEROCONVERSION; SINGLE DRUG DOSE; TERTIARY HEALTH CARE; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; VACCINATION;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; VACCINATION;

EID: 84861184246     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05110.x     Document Type: Article

References (45)

1. Lok AS, McMahon BJ,. Chronic hepatitis B. Hepatology 2007; 45: 507-39. (Pubitemid 46374607)
2. Hou JK, Velayos F, Terrault N, Mahadevan U,. Viral hepatitis and inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 925-32.
3. Rahier JF, Ben-Horin S, Chowers Y, et al,. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009; 3: 47-91.
4. Rahier JF, Moutschen M, Van Gompel A, et al,. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford) 2010; 49: 1815-27.
5. Mindikoglu AL, Regev A, Schiff ER,. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol 2006; 4: 1076-81. (Pubitemid 44311645)
6. Firpi RJ, Nelson DR,. Management of viral hepatitis in hematologic malignancies. Blood Rev 2008; 22: 117-26.
7. Kohrt HE, Ouyang DL, Keeffe EB,. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Clin Liver Dis 2007; 11: 965-91, x. (Pubitemid 350019026)
8. Viget N, Vernier-Massouille G, Salmon-Ceron D, Yazdanpanah Y, Colombel JF,. Opportunistic infections in patients with inflammatory bowel disease: prevention, diagnosis. Gut 2008; 57: 549-58. (Pubitemid 351442541)
9. Gisbert JP, Chaparro M, Esteve M,. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 619-33.
10. del Valle Garcia-Sanchez M, Gomez-Camacho F, Poyato-Gonzalez A, Iglesias-Flores EM, de Dios-Vega JF, Sancho-Zapatero R,. Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection. Inflamm Bowel Dis 2004; 10: 701-2. (Pubitemid 39294531)
11. Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM,. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 53: 1363-5. (Pubitemid 39120128)
12. Ueno Y, Tanaka S, Shimamoto M, et al,. Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B. Dig Dis Sci 2005; 50: 163-6. (Pubitemid 40379157)
13. Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W,. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol 2006; 12: 974-6.
14. Colbert C, Chavarria A, Berkelhammer C,. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease. Inflamm Bowel Dis 2007; 13: 1453-4. (Pubitemid 350206866)
15. Esteve M, Loras C, Gonzalez-Huix F,. Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohn's disease patient. Inflamm Bowel Dis 2007; 13: 1450-1. (Pubitemid 350206863)
16. Madonia S, Orlando A, Scimeca D, Olivo M, Rossi F, Cottone M,. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis 2007; 13: 508-9. (Pubitemid 46668261)
17. Ojiro K, Naganuma M, Ebinuma H, et al,. Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. J Gastroenterol 2008; 43: 397-401. (Pubitemid 351958904)
18. Loras C, Gisbert JP, Minguez M, et al,. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut 2010; 59: 1340-6.
19. Coates T, Wilson R, Patrick G, Andre F, Watson V,. Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin Ther 2001; 23: 392-403. (Pubitemid 32328745)
20. Mast EE, Weinbaum CM, Fiore AE, et al,. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006; 55: 1-33.
21. Hepatitis B vaccines: WHO position paper-recommendations. Vaccine 2009; 28: 589-90.
22. Shouval D,. Hepatitis B vaccines. J Hepatol 2003; 39: S70-6. (Pubitemid 37222650)
23. Wasan SK, Baker SE, Skolnik PR, Farraye FA,. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol 2010; 105: 1231-8.
24. Melmed GY,. Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. Inflamm Bowel Dis 2009; 15: 1410-6.
25. Bruguera M, Cremades M, Salinas R, Costa J, Grau M, Sans J,. Impaired response to recombinant hepatitis B vaccine in HIV-infected persons. J Clin Gastroenterol 1992; 14: 27-30.
26. Elkayam O, Yaron M, Caspi D,. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. Ann Rheum Dis 2002; 61: 623-5. (Pubitemid 34717774)
27. Stevens R, Oliver M, Brogan M, Heiserodt J, Targan S,. Defective generation of tetanus-specific antibody-producing B cells after in vivo immunization of Crohn's disease and ulcerative colitis patients. Gastroenterology 1985; 88: 1860-6. (Pubitemid 15052298)
28. Sands BE, Cuffari C, Katz J, et al,. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 677-92. (Pubitemid 39276481)
29. Dotan I, Werner L, Vigodman S, et al,. Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines. Inflamm Bowel Dis 2012; 18: 261-8.
30. Melmed GY, Ippoliti AF, Papadakis KA, et al,. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006; 101: 1834-40. (Pubitemid 44166594)
31. Vida Perez L, Gomez Camacho F, Garcia Sanchez V, et al,. Adequate rate of response to hepatitis B virus vaccination in patients with inflammatory bowel disease. Med Clin (Barc) 2009; 132: 331-5.
32. Zuin G, Principi N, Tornaghi R, et al,. Impaired response to hepatitis B vaccine in HIV infected children. Vaccine 1992; 10: 857-60.
33. Scolfaro C, Fiammengo P, Balbo L, Madon E, Tovo PA,. Hepatitis B vaccination in HIV-1-infected children: double efficacy doubling the paediatric dose. AIDS 1996; 10: 1169-70. (Pubitemid 26283357)
34. Bruguera M, Cremades M, Rodicio JL, et al,. Immunogenicity of a yeast-derived hepatitis B vaccine in hemodialysis patients. Am J Med 1989; 87: 30S-2S.
35. Choudhury SA, Peters VB,. Responses to hepatitis B vaccine boosters in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1995; 14: 65-7.
36. Fonseca MO, Pang LW, de Paula Cavalheiro N, Barone AA, Heloisa Lopes M,. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005; 23: 2902-8. (Pubitemid 40386492)
37. Rey D, Krantz V, Partisani M, et al,. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine 2000; 18: 1161-5. (Pubitemid 30001829)
38. Recommended adult immunization schedule: United States, 2010. Ann Intern Med 2010; 152: 36-9.
39. Bertino JS Jr, Tirrell P, Greenberg RN, et al,. A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S1, and pre-S2 particles for revaccination of healthy adult nonresponders. J Infect Dis 1997; 175: 678-81. (Pubitemid 27086174)
40. Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC,. What level of hepatitis B antibody is protective? J Infect Dis 1999; 179: 489-92. (Pubitemid 29086654)
41. John TJ, Cooksley G,. Hepatitis B vaccine boosters: is there a clinical need in high endemicity populations? J Gastroenterol Hepatol 2005; 20: 5-10. (Pubitemid 40143627)
42. Chen DS,. Hepatitis B vaccination: the key towards elimination and eradication of hepatitis B. J Hepatol 2009; 50: 805-16.
43. Chevaux JB, Nani A, Oussalah A, et al,. Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France. Inflamm Bowel Dis 2010; 16: 916-24.
44. Zuckerman JN, Sabin C, Craig FM, Williams A, Zuckerman AJ,. Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: Randomised double blind dose-response study. BMJ 1997; 314: 329-33. (Pubitemid 27056553)
45. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet 2000; 355: 561-5.